US$ 27.26
what companies make glp-1 drugs Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 16 Best Places to Get
Description
The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide

Market Volume (Sales Units) estimates and 10-year revenue forecasts from 2026 to 2036, validated through manufacturer shipment data, channel partner surveys, and country-level demand modeling

Cardiovascular outcome trials (CVOTs) in patients living with T2DM have confirmed that GLP-1R agonists decrease cardiovascular mortality and reduce the incidence of myocardial infarction (MI) and stroke
Patients should discuss long-term goals and monitoring plans with prescribing clinicians to align treatment with individual risk profiles

Dungan K, DeSantis A
Wilding JPH, Batterham RL, Davies M et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
